Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

News Press Release Media Report

Year:

Select

Press Release

26 March 2024

Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033 the nature of subcutaneous injectable will lead to improved safety and convenience
22 March 2024

The Results of Phase II Clinical Study of KN046 Plus Chemotherapy as First-line Treatment for Metastatic NSCLC were Published in Cell Reports Medicine this phase II study could be a promising treatment option for this patient population
14 March 2024

Alphamab Oncology to Present Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors at AACR 2024 Clinical data from the dose-escalation stage (phase Ia) of this study will be presented at this AACR conference
06 February 2024

The Results of Phase II Clinical Study of KN046 in Combination with Nab-paclitaxel in TNBC were Published in Nature Communications KN046 combined with nab-paclitaxel in the first-line treatment of TNBC showed encouraging PFS and OS
25 Janurary 2024

Alphamab Oncology and 3DMedicines Entered into a Licensing Agreement with Glenmark for KN035 The notable advantages of Envafolimab in terms of safety, convenience, and compliance position it as a competitive product.
09 Janurary 2024

Alphamab Oncology Announced Innovative Bispecific Antibody Coupling Drug JSKN016 Clinical Study Accepted by CDE JSKN016 is a bispecific antibody conjugated drug (ADC) targeting HER3 and TROP2
11 December 2023

Alphamab's Novel Subcutaneous Anti-HER2 Bispecific ADC JSKN033 Approved for Clinical Studies in Australia JSKN033 is a subcutaneous injection compound consisting of JSKN003 and envafolimab
07 December 2023

Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer KN026 in combination with docetaxel is well tolerated and has shown promising clinical benefit as 1L treatment for HER2-positive BC
04 December 2023

First Patient Dosed in Phase Ⅲ Study of JSKN003 for the Treatment of Advanced HER2-Low Breast Cancer is a phase III clinical study in patients with unresectable locally advanced or metastatic HER2 low-expressing breast cancer
07 November 2023

KN026 was Granted Breakthrough Therapy Designation by CDE KN026 is expected to become the first anti-HER2 treatment for second-line gastric cancer where HER2-targeted therapy has failed.